{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:07:45Z","timestamp":1764493665892},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,2,5]],"date-time":"2011-02-05T00:00:00Z","timestamp":1296864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00044-011-9580-x","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T02:36:30Z","timestamp":1296786990000},"page":"739-746","source":"Crossref","is-referenced-by-count":8,"title":["QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors"],"prefix":"10.1007","volume":"21","author":[{"given":"N. S. Hari Narayana","family":"Moorthy","sequence":"first","affiliation":[]},{"given":"Nuno M. F. S. A.","family":"Cerqueira","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Pedro A.","family":"Fernandes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,2,5]]},"reference":[{"key":"9580_CR1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","volume":"20","author":"G Alexander","year":"2002","unstructured":"Alexander G, Alexander T (2002) Beware of Q2. J Mol Graphs Model 20:269\u2013276","journal-title":"J Mol Graphs Model"},{"key":"9580_CR2","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.bmcl.2004.09.068","volume":"14","author":"S Balaji","year":"2004","unstructured":"Balaji S, Karthikeyan C, Moorthy NSHN, Trivedi P (2004) QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 14:6089\u20136094","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"9580_CR3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2174\/0929867054020981","volume":"12","author":"NMFSA Cerqueira","year":"2005","unstructured":"Cerqueira NMFSA, Pereira S, Fernandes PA, Ramos MJ (2005) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 12(11):1283\u20131294","journal-title":"Curr Med Chem"},{"issue":"42","key":"9580_CR4","doi-asserted-by":"crossref","first-page":"21272","DOI":"10.1021\/jp0608269","volume":"110","author":"NMFSA Cerqueira","year":"2006","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2006) Enzyme ribonucleotide reductase: unraveling an enigmatic paradigm of enzyme inhibition by furanone derivatives. J Phys Chem B 110(42):21272\u201321281","journal-title":"J Phys Chem B"},{"key":"9580_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/157489207779561408","volume":"2","author":"NMFSA Cerqueira","year":"2007","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007a) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2:11\u201329","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"30","key":"9580_CR6","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NMFSA Cerqueira","year":"2007","unstructured":"Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007b) Understanding ribonucleotide reductase inactivation by gemcitabine. Chem Eur J 13(30):8507\u20138515","journal-title":"Chem Eur J"},{"issue":"365","key":"9580_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/01621459.1979.10481634","volume":"74","author":"RD Cook","year":"1979","unstructured":"Cook RD (1979) Influential observation in linear regression. J Am Stat Assoc 74(365):169\u2013174","journal-title":"J Am Stat Assoc"},{"issue":"1\u20132","key":"9580_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-1280(99)00360-7","volume":"503","author":"G Cruciani","year":"2000","unstructured":"Cruciani G, Crivori P, Carrupt PA, Testa B (2000a) Molecular fields in quantitative structure permeation relationships: the Volsurf approach. J Mol Struct: Theochem 503(1\u20132):17\u201330","journal-title":"J Mol Struct: Theochem"},{"issue":"2","key":"9580_CR9","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0928-0987(00)00162-7","volume":"11","author":"G Cruciani","year":"2000","unstructured":"Cruciani G, Pastor M, Guba W (2000b) Volsurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 11(2):S29\u2013S39","journal-title":"Eur J Pharm Sci"},{"key":"9580_CR10","first-page":"409","volume":"37","author":"J Durbin","year":"1950","unstructured":"Durbin J, Watson GS (1950) Testing for serial correlation in least squares regression. I. Biometrika 37:409\u2013428","journal-title":"I. Biometrika"},{"key":"9580_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/biomet\/38.1-2.159","volume":"38","author":"J Durbin","year":"1951","unstructured":"Durbin J, Watson GS (1951) Testing for serial correlation in least squares regression II. Biometrika 38:159\u2013179","journal-title":"Biometrika"},{"issue":"20","key":"9580_CR12","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1021\/ja0208613","volume":"125","author":"PA Fernandes","year":"2003","unstructured":"Fernandes PA, Ramos MJ (2003) Theoretical studies on the mechanism of Inhibition of ribonucleotide reductase by (E)-2\u2032-fluromethylene-2\u2032-deoxycitidine-5\u2032-diphosphate. J Am Chem Soc 125(20):6311\u20136322","journal-title":"J Am Chem Soc"},{"key":"9580_CR13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","volume":"59","author":"RA Finch","year":"2000","unstructured":"Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad- spectrum antitumor activity. Biochem Pharmacol 59:983\u2013991","journal-title":"Biochem Pharmacol"},{"key":"9580_CR14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/qsar.200960057","volume":"28","author":"HM Ishiki","year":"2009","unstructured":"Ishiki HM, do Amaral AT (2009) Three-dimensional quantitative structure activity relationship study of antitumor 2-formylpyridine thiosemicarbazones derivatives as inhibitors of ribonucleotide reductase. QSAR Comb Sci 28:1334\u20131345","journal-title":"QSAR Comb Sci"},{"issue":"1\u20132","key":"9580_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbapap.2004.02.007","volume":"1699","author":"M Kolberg","year":"2004","unstructured":"Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function and mechanism of ribonucleotide reductases. Biochimica et Biophysica Acta (BBA) Proteins Proteomics 1699(1\u20132):1\u201334","journal-title":"Biochimica et Biophysica Acta (BBA) Proteins Proteomics"},{"key":"9580_CR16","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1016\/j.bmcl.2008.09.097","volume":"18","author":"K Krishnan","year":"2008","unstructured":"Krishnan K, Prathiba K, Jayaprakash V, Basu A, Nibha M, Zhou B, Hu S, Yen Y (2008) Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazone. Bioorg Med Chem Lett 18:6248\u20136250","journal-title":"Bioorg Med Chem Lett"},{"key":"9580_CR17","unstructured":"Lin A (2002) QuaSAR-descriptors. J Chem Comput Group. http:\/\/www.chemcomp.com\/Journal_of_CCG\/Features\/descr.htm"},{"key":"9580_CR18","unstructured":"MOE 2007.02 Chemical Computing Group Inc., Montreal, H3A 2R7 Canada, http:\/\/www.chemcomp.com"},{"key":"9580_CR19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1040-8428(98)00032-8","volume":"29","author":"P Navarra","year":"1999","unstructured":"Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249\u2013255","journal-title":"Crit Rev Oncol Hematol"},{"key":"9580_CR20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","volume":"75","author":"P Norlund","year":"2006","unstructured":"Norlund P, Reichard P (2006) Ribonucleotide reductase. Annu Rev Biochem 75:681\u2013706","journal-title":"Annu Rev Biochem"},{"key":"9580_CR21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2091-6-8","volume":"6","author":"T Radivoyevitch","year":"2005","unstructured":"Radivoyevitch T, Kashlan OB, Cooperman BS (2005) Rational polynomial representation of ribonucleotide reductase activity. BMC Biochem 6:8","journal-title":"BMC Biochem"},{"key":"9580_CR22","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1021\/jm030016a","volume":"46","author":"AV Raichurkar","year":"2003","unstructured":"Raichurkar AV, Kulkarni VM (2003) Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. J Med Chem 46:4419\u20134427","journal-title":"J Med Chem"},{"key":"9580_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/jm010252q","volume":"45","author":"S Ren","year":"2002","unstructured":"Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna EE, Csipke C, Tokes ZA, Lien EJ (2002) Synthesis, biological evaluation and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem 45:410\u2013419","journal-title":"J Med Chem"},{"key":"9580_CR24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","volume":"41","author":"MO Robert","year":"2007","unstructured":"Robert MO (2007) A caution regarding rules of thumb for variance inflation factors. Qual Quant 41:673\u2013690","journal-title":"Qual Quant"},{"key":"9580_CR25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","volume":"6","author":"J Shao","year":"2006","unstructured":"Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409\u2013431","journal-title":"Curr Cancer Drug Targets"},{"key":"9580_CR26","unstructured":"Statistica 8.0 statistical software (2008) StatSoft, Inc, Tulsa, OK, USA"},{"key":"9580_CR27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/10408369709006424","volume":"34","author":"T Szekeres","year":"1997","unstructured":"Szekeres T, Fritzer-Szekeres M, Elford HL (1997) The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 34:503\u2013528","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9580_CR28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/14737140.2.4.437","volume":"2","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, Alvarado Y, Giles FJ (2002) Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2:437\u2013448","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"9580_CR29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/ci990307l","volume":"39","author":"SA Wildman","year":"1999","unstructured":"Wildman SA, Crippen GM (1999) Prediction of physiochemical parameters by atomic contributions. J Chem Inf Comput Sci 39(5):868\u2013873","journal-title":"J Chem Inf Comput Sci"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-011-9580-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00044-011-9580-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-011-9580-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T11:26:31Z","timestamp":1558524391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00044-011-9580-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,5]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9580"],"URL":"https:\/\/doi.org\/10.1007\/s00044-011-9580-x","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,5]]}}}